Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 2 von 14
Clinical pharmacology and therapeutics, 1987-03, Vol.41 (3), p.282-288
1987
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics
Ist Teil von
  • Clinical pharmacology and therapeutics, 1987-03, Vol.41 (3), p.282-288
Ort / Verlag
New York, NY: Nature Publishing
Erscheinungsjahr
1987
Quelle
MEDLINE
Beschreibungen/Notizen
  • Fenoldopam, a dopaminergic agonist, was administered intravenously to 18 healthy male subjects in doses ranging from 0.025 to 1.0 μg/kg/min for 2 hours. Three subjects were studied in a three‐way crossover of fenoldopam at doses of 0.025, 0.10, and 0.50 μg/kg/min. Fenoldopam decreased diastolic blood pressure and increased pulse rate without changing systolic blood pressure. Fenoldopam produced dose‐related increases in para‐aminohippuric acid clearance up to 75% at the 0.50 μg/kg/min dose. This increase in renal blood flow was accompanied by increases in urine volume, water, and solute excretion; glomerular filtration rate was unchanged. Doses greater than 0.25 μg/kg/min caused flushing and nasal congestion. The dopamine receptor antagonist metoclopramide (0.1 mg/kg/hr) did not block the systemic hemodynamic effects of fenoldopam but attenuated the increase in para‐aminohippuric acid clearance. Fenoldopam plasma levels achieved steady state between 30 and 120 minutes after the start of the infusion and were linear with respect to infusion rate. Our findings show that intravenous fenoldopam causes systemic arteriolar vasodilation, accompanied by renal vasodilation and increased sodium excretion. Clinical Pharmacology and Therapeutics (1987) 41, 282–288; doi:10.1038/clpt.1987.29

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX